A subgroup analysis of the SENSCIS trial showed that nintedanib slows decline of lung function in patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD) independent of intake of corticosteroids .
ILD is a frequent manifestation of SSc and the leading cause of death in these patients. Nintedanib is an antifibrotic agent that is approved for therapy of idiopathic lung fibrosis. In the SENSCIS trial, the largest trial ever performed in patients with SSc-ILD, nintedanib slowed the decline in forced vital capacity (FVC) by 44% . During the ACR meeting, a subgroup analysis assessed the benefit of antifibrotic therapy according to corticosteroid use . Patients with SSc-ILD with ≥10% fibrosis of the lungs on high-resolution computer tomography were randomised to receive nintedanib 150 mg twice daily or placebo. Patients taking prednisone ≤10 mg/day or equivalent were allowed to participate. Lung function outcomes and adverse events (irrespective of causality) were analysed in subgroups of patients who did and did not use corticosteroids.
A total of 71.5% of patients in the nintedanib group and 66.3% in the placebo group also used corticosteroids. Mean FVC at baseline was 2,499 mL in patients who used corticosteroids and 2,501 mL in patients who did not. Nintedanib reduced the annual rate of decline in FVC (mL/year) versus placebo both in patients who did and did not use corticosteroids, with no difference in the treatment effect between subgroups detected (treatment-by-time-by-subgroup interaction P=0.82; see Figure).
The adverse event profile of nintedanib was similar between the subgroups by corticosteroid use, but the proportions of patients with nausea or vomiting adverse events were lower, and the proportion with upper respiratory tract infection was higher, in those who used corticosteroids. The authors concluded that antifibrotic therapy shows similar efficacy and tolerability independent of therapy with corticosteroids.
Figure: Annual rate of decline in FVC (mL/year) over 52 weeks in the SENSCIS trial in subgroups by use of corticosteroids 
FVC, forced vital capacity; CI, confidence interval; SE, standard error
- Vonk M, et al. Abstract 1643. ACR 2019. 8-13 November, Atlanta (GA/USA).
- Distler O, et al. N Engl J Med 2019;380:2518-28.
« Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis Next Article
Lowest risk of infection after therapy with an IL-12/IL-23 blocker »
Table of Contents: ACR 2019
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications
Proteome abnormalities improve prediction of RA development
RA patients in remission benefit from continued therapy with conventional DMARDs
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
Corticosteroid therapy in GCA: higher platelets – lower relapse rate
Spotlight on Rheumatoid Arthritis
Filgotinib promising in RA patients naïve to methotrexate
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
Biologics show similar activity in patients with elderly-onset RA
Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration
Treatment decisions should not be guided by ultrasound findings
Cancer treatment with checkpoint inhibitors in RA patients?
What is Hot in Systemic Lupus Erythematosus
Anifrolumab succeeds in second phase 3 trial in SLE
Depression closely related to fatigue in SLE patients
Spondyloarthritis – The Beat Goes On
Psoriasis onset determines sequence of symptoms
Higher psychiatric comorbidity in women with PsA
JAK1 inhibition shows remarkable efficacy in AS
CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients
Osteoarthritis – State-of-the-Art
Hand OA: low-dose corticosteroids improve symptoms
Opioids: no quality of life benefits for OA patients
Walking speed is a predictor of mortality in patients with knee OA
Reproductive Issues in Rheumatic Disease
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Prevention of congenital heart block may be possible with hydroxychloroquine
TNFi for RA during pregnancy – to stop or not to stop?
Vasculitis – Novel Treatment Modalities
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis
Prolonged remission after stop of tocilizumab for patients with giant cell arteritis
Best of the Posters
Antifibrotic therapy slows disease progression independent of corticosteroid use
Fibromyalgia patients often experienced abuse in childhood
Genetically engineered cells deliver RA drug in mouse study